Market Overview

Research and Markets: Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology


Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology" to their offering.

Monoclonal antibodies (MAbs) in oncology are highly commercially successful2010 sales of major MAbs (rituximab [Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan/MabThera], trastuzumab [Roche/Genentech/Chugai's Herceptin], cetuximab [Bristol-Myers Squibb/ImClone/Eli Lilly/Merck Serono's Erbitux], and bevacizumab [Roche/Genentech/Chugai's Avastin]) across the seven major pharmaceutical markets that we cover (United States, EU5 [France, Germany, Italy, Spain, United Kingdom], and Japan) reached nearly $15 billion, making them a prime target for biosimilars manufacturers.

Combined sales of granulocyte colony-stimulating factors (G-CSFs) (Amgen's Neupogen [filgrastim] and Neulasta [pegfilgrastim]) were approximately $4.6 billion in 2010 despite active biosimilar competition in Europe for filgrastim. Over the course of our 2010-2020 forecast period, we anticipate biosimilar MAbs will gain the second-highest commercial reward of any of the biosimilar classes expected to be on the market. Although market share for biosimilar MAbs in oncology will not reach the same depth of penetration expected for biosimilar G-CSFs, biosimilar versions of G-CSFs will be less commercially successful based on the lower brand sales forecasts through 2020.

Nevertheless, newly launching biosimilar versions of G-CSFs and MAbs will save healthcare systems $3.8 billion in 2020 across the seven pharmaceutical markets. Total sales across the major pharmaceutical markets for biosimilar G-CSFs and MAbs are forecast to reach in excess of $6.5 billion in 2020.

The primary research presented in this report is gathered from a quantitative, online, 40-minute survey with 76 solid-tumor oncologists and 78 hematologist-oncologists from the United States, France, and Germany.

Key Topics Covered:

1. Key Findings

2. Introduction and Methodology

3. Oncologist Perspectives

Current Reimbursement of Biologics in Oncology

Current Understanding of Biosimilars

Expectations for Biosimilar Trials

Attitudes of Key Stakeholders

Anticipated Initial Use of Biosimilars

Eventual Use of Biosimilars

Reasons for Current Slow Adoption of Biosimilars

4. Market Forecast

Overview of Biosimilar Erosion Across Major Markets

Forecast Assumptions

Branded and Biosimilar G-CSFs

Branded and Biosimilar MAbs

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals, Oncology

View Comments and Join the Discussion!